# Novel synergistic interactions between monolaurin, a mono-acyl glycerol and β lactam antibiotics against Staphylococcus aureus: an in vitro study

**Authors:** Shimaa Salah Hassan Abd El Ghany, Reham A. Ibrahem, Ahmed Osama EL-Gendy, Rehab Mahmoud Abd El-Baky, Ahmad Mustafa, Ahmed Farag Azmy

PMC · DOI: 10.1186/s12879-024-09261-9 · 2024-04-08

## TL;DR

This study shows that combining monolaurin with beta-lactam antibiotics can effectively fight Staphylococcus aureus, including drug-resistant strains.

## Contribution

The study identifies monolaurin as a synergistic modulator of beta-lactam antibiotics against S. aureus.

## Key findings

- Monolaurin's MIC against S. aureus ranged from 250 to 2000 µg/ml.
- Combination therapy reduced MIC values and showed synergistic effects in 83.3% to 100% of cases.
- Monolaurin significantly decreased blaZ gene expression in S. aureus isolates.

## Abstract

A major worldwide health issue is the rising frequency of resistance of bacteria.Drug combinations are a winning strategy in fighting resistant bacteria and might help in protecting the existing drugs.Monolaurin is natural compound extracted from coconut oil and has a promising antimicrobial activity against Staphylococcus.aureus. This study aims to examine the efficacy of monolaurin both individually and in combination with β-lactam antibiotics against Staphylococcus aureus isolates.

Agar dilution method was used for determination of minimum inhibitory concentration (MIC) of monolaurin against S.aureus isolates. Scanning electron microscope (SEM) was used to detect morphological changes in S.aureus after treatment with monolaurin. Conventional and Real-time Polymerase chain reaction (RT-PCR) were performed to detect of beta-lactamase (blaZ) gene and its expressional levels after monolaurin treatment. Combination therapy of monolaurin and antibiotics was assessed through fractional inhibitory concentration and time-kill method.

The antibacterial activity of monolaurin was assessed on 115 S.aureus isolates, the MIC of monolaurin were 250 to 2000 µg/ml. SEM showed cell elongation and swelling in the outer membrane of S.aureus in the prescence of 1xMIC of monolaurin. blaZ gene was found in 73.9% of S.aureus isolates. RT-PCR shows a significant decrease in of blaZ gene expression at 250 and 500 µg/ml of monolaurin. Synergistic effects were detected through FIC method and time killing curve. Combination therapy established a significant reduction on the MIC value. The collective findings from the antibiotic combinations with monolaurin indicated synergism rates ranging from 83.3% to 100%.In time-kill studies, combination of monolaurin and β-lactam antibiotics produced a synergistic effect.

This study showed that monolaurin may be a natural antibacterial agent against S. aureus, and may be an outstanding modulator of β-lactam drugs. The concurrent application of monolaurin and β-lactam antibiotics, exhibiting synergistic effects against S. aureus in vitro, holds promise as potential candidates for the development of combination therapies that target particularly, patients with bacterial infections that are nearly incurable.

The online version contains supplementary material available at 10.1186/s12879-024-09261-9.

## Linked entities

- **Genes:** blaZ (penicillin-hydrolyzing class A beta-lactamase BlaZ) [NCBI Gene 48886948]
- **Chemicals:** monolaurin (PubChem CID 14871)
- **Species:** Staphylococcus aureus (taxon 1280)

## Full-text entities

- **Genes:** blaZ [NCBI Gene 13874473], beta-lactamase [NCBI Gene 13913583]
- **Diseases:** bacterial infections (MESH:D001424)
- **Chemicals:** coconut oil (MESH:D000074263), Monolaurin (MESH:C020777), mono-acyl glycerol (MESH:D050178), 1xMIC (-), beta lactam (MESH:D047090)
- **Species:** Staphylococcus aureus (species) [taxon 1280], Homo sapiens (human, species) [taxon 9606], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11000382/full.md

---
Source: https://tomesphere.com/paper/PMC11000382